{"entity":{"type":"insider","cik":"0001814876","url":"/insider/0001814876","json_url":"/insider/0001814876.json","name":"Coyne Terrance P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":50,"n_filings":22,"first":"2020-06-23","last":"2026-08-17","span_basis":"filed_date"},"name_variants":[{"name":"Coyne Terrance P.","source":"filing","n_filings":22,"first_seen":"2020-06-23","last_seen":"2026-08-17"}],"transactions":[{"id":9296084,"accession":"0001814876-26-000027","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001814876-26-000027","line_url":"/filing/0001814876-26-000027","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11002.0,"shares_display":"11,002","price_per_share":58.675805308125796,"price_display":"58.68","price_state":"stated","total_value":645551.21,"total_display":"645,551.21","total_whole":"645,551","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-13","filed_date":"2026-08-17","scope":"insider","n_lines":2},{"id":5911765,"accession":"0001814876-26-000022","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001814876-26-000022","line_url":"/filing/0001814876-26-000022#line-1","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":64399.0,"shares_display":"64,399","price_per_share":53.9778,"price_display":"53.98","price_state":"stated","total_value":3476116.3422,"total_display":"3,476,116.34","total_whole":"3,476,116","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-26","filed_date":"2026-05-28","scope":"insider"},{"id":5996634,"accession":"0001814876-26-000018","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001814876-26-000018","line_url":"/filing/0001814876-26-000018","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34791.0,"shares_display":"34,791","price_per_share":49.7784,"price_display":"49.78","price_state":"stated","total_value":1731840.3144,"total_display":"1,731,840.31","total_whole":"1,731,840","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-28","filed_date":"2026-04-30","scope":"insider","n_lines":2},{"id":5911763,"accession":"0001814876-26-000016","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001814876-26-000016","line_url":"/filing/0001814876-26-000016","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34791.0,"shares_display":"34,791","price_per_share":48.3318,"price_display":"48.33","price_state":"stated","total_value":1681511.6538,"total_display":"1,681,511.65","total_whole":"1,681,512","shares_owned_after":32916.0,"shares_owned_after_display":"32,916","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-01","filed_date":"2026-04-02","scope":"insider","n_lines":2},{"id":5876637,"accession":"0001814876-26-000014","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001814876-26-000014","line_url":"/filing/0001814876-26-000014","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34791.0,"shares_display":"34,791","price_per_share":45.5287,"price_display":"45.53","price_state":"stated","total_value":1583989.0017,"total_display":"1,583,989.00","total_whole":"1,583,989","shares_owned_after":65832.0,"shares_owned_after_display":"65,832","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-23","filed_date":"2026-03-25","scope":"insider","n_lines":2},{"id":6062294,"accession":"0001814876-26-000012","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001814876-26-000012","line_url":"/filing/0001814876-26-000012","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34791.0,"shares_display":"34,791","price_per_share":46.78031064643155,"price_display":"46.78","price_state":"stated","total_value":1627533.7877,"total_display":"1,627,533.79","total_whole":"1,627,534","shares_owned_after":109177.0,"shares_owned_after_display":"109,177","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-02","filed_date":"2026-03-04","scope":"insider","n_lines":4},{"id":5996628,"accession":"0001814876-26-000010","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001814876-26-000010","line_url":"/filing/0001814876-26-000010","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34791.0,"shares_display":"34,791","price_per_share":45.3165,"price_display":"45.32","price_state":"stated","total_value":1576606.3515,"total_display":"1,576,606.35","total_whole":"1,576,606","shares_owned_after":131664.0,"shares_owned_after_display":"131,664","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-23","filed_date":"2026-02-25","scope":"insider","n_lines":2},{"id":5923993,"accession":"0001814876-26-000006","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001814876-26-000006","line_url":"/filing/0001814876-26-000006","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20163.0,"shares_display":"20,163","price_per_share":43.2928,"price_display":"43.29","price_state":"stated","total_value":872912.7264,"total_display":"872,912.73","total_whole":"872,913","shares_owned_after":164580.0,"shares_owned_after_display":"164,580","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-04","filed_date":"2026-02-04","scope":"insider","n_lines":2},{"id":5923989,"accession":"0001814876-26-000006","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001814876-26-000006","line_url":"/filing/0001814876-26-000006","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":114954.0,"shares_display":"114,954","price_per_share":42.843194610887835,"price_display":"42.84","price_state":"stated","total_value":4924996.5933,"total_display":"4,924,996.59","total_whole":"4,924,997","shares_owned_after":183656.0,"shares_owned_after_display":"183,656","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-03","filed_date":"2026-02-04","scope":"insider","n_lines":2},{"id":5923987,"accession":"0001814876-26-000006","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001814876-26-000006","line_url":"/filing/0001814876-26-000006","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":108424.0,"shares_display":"108,424","price_per_share":42.0839,"price_display":"42.08","price_state":"stated","total_value":4562904.7736,"total_display":"4,562,904.77","total_whole":"4,562,905","shares_owned_after":292415.0,"shares_owned_after_display":"292,415","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-02","filed_date":"2026-02-04","scope":"insider","n_lines":2},{"id":5791868,"accession":"0001814876-26-000004","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001814876-26-000004","line_url":"/filing/0001814876-26-000004","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":69582.0,"shares_display":"69,582","price_per_share":39.3484,"price_display":"39.35","price_state":"stated","total_value":2737940.3688,"total_display":"2,737,940.37","total_whole":"2,737,940","shares_owned_after":394996.0,"shares_owned_after_display":"394,996","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-01-20","filed_date":"2026-01-23","scope":"insider","n_lines":2},{"id":5876634,"accession":"0001814876-26-000002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001814876-26-000002","line_url":"/filing/0001814876-26-000002","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":69582.0,"shares_display":"69,582","price_per_share":38.4157,"price_display":"38.42","price_state":"stated","total_value":2673041.2374,"total_display":"2,673,041.24","total_whole":"2,673,041","shares_owned_after":460828.0,"shares_owned_after_display":"460,828","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-01-02","filed_date":"2026-01-06","scope":"insider","n_lines":2},{"id":4971021,"accession":"0001814876-25-000011","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001814876-25-000011","line_url":"/filing/0001814876-25-000011","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":69582.0,"shares_display":"69,582","price_per_share":38.3601,"price_display":"38.36","price_state":"stated","total_value":2669172.4782,"total_display":"2,669,172.48","total_whole":"2,669,172","shares_owned_after":526660.0,"shares_owned_after_display":"526,660","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-15","filed_date":"2025-12-17","scope":"insider","n_lines":2},{"id":4186672,"accession":"0001814876-25-000009","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001814876-25-000009","line_url":"/filing/0001814876-25-000009","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":69582.0,"shares_display":"69,582","price_per_share":39.866,"price_display":"39.87","price_state":"stated","total_value":2773956.012,"total_display":"2,773,956.01","total_whole":"2,773,956","shares_owned_after":592492.0,"shares_owned_after_display":"592,492","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-01","filed_date":"2025-12-03","scope":"insider","n_lines":2},{"id":4053441,"accession":"0001814876-25-000007","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001814876-25-000007","line_url":"/filing/0001814876-25-000007","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":69582.0,"shares_display":"69,582","price_per_share":38.551715236699145,"price_display":"38.55","price_state":"stated","total_value":2682505.4496,"total_display":"2,682,505.45","total_whole":"2,682,505","shares_owned_after":669010.0,"shares_owned_after_display":"669,010","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-24","filed_date":"2025-11-26","scope":"insider","n_lines":4},{"id":4517288,"accession":"0001814876-25-000005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001814876-25-000005","line_url":"/filing/0001814876-25-000005","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":69594.0,"shares_display":"69,594","price_per_share":39.30409461160445,"price_display":"39.30","price_state":"stated","total_value":2735329.1604,"total_display":"2,735,329.16","total_whole":"2,735,329","shares_owned_after":724156.0,"shares_owned_after_display":"724,156","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-17","filed_date":"2025-11-19","scope":"insider","n_lines":2},{"id":7973171,"accession":"0001209191-23-045463","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-045463","line_url":"/filing/0001209191-23-045463#line-2","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37500.0,"shares_display":"37,500","price_per_share":30.7491,"price_display":"30.75","price_state":"stated","total_value":1153091.25,"total_display":"1,153,091.25","total_whole":"1,153,091","shares_owned_after":790000.0,"shares_owned_after_display":"790,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-08-10","filed_date":"2023-08-11","scope":"insider"},{"id":7973167,"accession":"0001209191-23-045463","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-045463","line_url":"/filing/0001209191-23-045463#line-1","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37500.0,"shares_display":"37,500","price_per_share":30.7183,"price_display":"30.72","price_state":"stated","total_value":1151936.25,"total_display":"1,151,936.25","total_whole":"1,151,936","shares_owned_after":827500.0,"shares_owned_after_display":"827,500","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-08-09","filed_date":"2023-08-11","scope":"insider"},{"id":7922856,"accession":"0001209191-23-042297","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-042297","line_url":"/filing/0001209191-23-042297#line-2","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37500.0,"shares_display":"37,500","price_per_share":30.9322,"price_display":"30.93","price_state":"stated","total_value":1159957.5,"total_display":"1,159,957.50","total_whole":"1,159,958","shares_owned_after":865000.0,"shares_owned_after_display":"865,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-07-13","filed_date":"2023-07-14","scope":"insider"},{"id":7922852,"accession":"0001209191-23-042297","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-042297","line_url":"/filing/0001209191-23-042297#line-1","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37500.0,"shares_display":"37,500","price_per_share":31.0735,"price_display":"31.07","price_state":"stated","total_value":1165256.25,"total_display":"1,165,256.25","total_whole":"1,165,256","shares_owned_after":902500.0,"shares_owned_after_display":"902,500","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-07-12","filed_date":"2023-07-14","scope":"insider"},{"id":6497803,"accession":"0001209191-22-056420","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-056420","line_url":"/filing/0001209191-22-056420#line-1","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24500.0,"shares_display":"24,500","price_per_share":43.4699,"price_display":"43.47","price_state":"stated","total_value":1065012.55,"total_display":"1,065,012.55","total_whole":"1,065,013","shares_owned_after":940000.0,"shares_owned_after_display":"940,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-08","filed_date":"2022-11-10","scope":"insider"},{"id":6787907,"accession":"0001209191-22-055873","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-055873","line_url":"/filing/0001209191-22-055873#line-1","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5500.0,"shares_display":"5,500","price_per_share":43.0629,"price_display":"43.06","price_state":"stated","total_value":236845.95,"total_display":"236,845.95","total_whole":"236,846","shares_owned_after":964500.0,"shares_owned_after_display":"964,500","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-02","filed_date":"2022-11-04","scope":"insider"},{"id":6502827,"accession":"0000899243-22-027643","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-027643","line_url":"/filing/0000899243-22-027643#line-1","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":43.1909,"price_display":"43.19","price_state":"stated","total_value":1295727.0,"total_display":"1,295,727.00","total_whole":"1,295,727","shares_owned_after":970000.0,"shares_owned_after_display":"970,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-01","filed_date":"2022-08-03","scope":"insider"},{"id":5433100,"accession":"0000950103-21-003634","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950103-21-003634","line_url":"/filing/0000950103-21-003634","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":44.784503199,"price_display":"44.78","price_state":"stated","total_value":4478450.3199,"total_display":"4,478,450.32","total_whole":"4,478,450","shares_owned_after":212457.0,"shares_owned_after_display":"212,457","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-03-03","filed_date":"2021-03-05","scope":"insider","n_lines":4},{"id":4870564,"accession":"0000950103-21-003568","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950103-21-003568","line_url":"/filing/0000950103-21-003568","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":46.940901414,"price_display":"46.94","price_state":"stated","total_value":4694090.1414,"total_display":"4,694,090.14","total_whole":"4,694,090","shares_owned_after":305022.0,"shares_owned_after_display":"305,022","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-03-02","filed_date":"2021-03-04","scope":"insider","n_lines":2},{"id":2290099,"accession":"0000950103-20-012254","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950103-20-012254","line_url":"/filing/0000950103-20-012254","is_derivative":false,"issuer_cik":"0001802768","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001802768","owner_cik":"0001814876","owner_name":"Coyne Terrance P.","owner_display_name":"Coyne Terrance P.","owner_url":"/insider/0001814876","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Class A Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2950.0,"shares_display":"2,950","price_per_share":28.0,"price_display":"28.00","price_state":"stated","total_value":82600.0,"total_display":"82,600.00","total_whole":"82,600","shares_owned_after":1500.0,"shares_owned_after_display":"1,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-06-18","filed_date":"2020-06-23","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":50,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":48,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":50},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001802768","name":"Royalty Pharma plc","url":"/issuer/0001802768","role":"Officer (EVP & CFO)","n_filings":22,"first_seen":"2020-06-23","last_seen":"2026-08-17"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001814876","retrieved_at":"2026-08-25T16:08:17+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}